Invasive Cervical Cancers After an HPV ‐Negative Test: Insights From HPV Testing Histories
Open Access
- 10 October 2026
- journal article
- research article
- Published by Wiley in International Journal of Cancer
Abstract
Human papillomavirus (HPV) testing is the primary method for cervical screening, and a negative HPV test is associated with a very low subsequent risk of invasive cancer. Nevertheless, some cervical cancers are diagnosed following an HPV‐negative test. Using Swedish registry data, we identified women diagnosed with invasive cervical cancer between 2019 and 2024 and reconstructed HPV testing histories from the National Cervical Screening Registry. The HPV test closest to diagnosis, performed before or within 30 days after diagnosis, was defined as the index test. Of 3000 women diagnosed with invasive cervical cancer, 243 (8.1%) had an HPV‐negative index test. These women were older and more frequently diagnosed at advanced stages than women with an HPV‐positive index test. After adjustment for age, calendar year, and histology, an HPV‐negative index test remained associated with advanced‐stage disease (adjusted OR 2.91, 95% CI: 2.13–4.00). Among women with an HPV‐negative index test, 128 of 243 (52.7%) had no prior HPV testing recorded, 83 of 243 (34.2%) had consistently HPV‐negative histories, and 32 of 243 (13.2%) had prior HPV positivity. Cytology records were available for 229 to 243 (94.2%), and 33 to 243 (13.6%) had a previous high‐grade histopathological diagnosis. Among women with an HPV‐negative index test, recurrent HPV positivity following an intervening negative test was observed in only one woman. Cervical cancers diagnosed after an HPV‐negative test reflect heterogeneous HPV testing histories. Most women either had no prior HPV testing recorded or had consistently HPV‐negative results, while HPV positivity was observed in a smaller subgroup.Keywords
This publication has 9 references indexed in Scilit:
- Cervical Human Papillomavirus–Independent Squamous Cell Carcinoma: A Clinicopathological Review and Outcomes Analysis Compared With Human Papillomavirus–Associated Squamous Cell CarcinomaLaboratory Investigation, 2025
- Nationwide registry‐based trial of risk‐stratified cervical screeningInternational Journal of Cancer, 2024
- Human papillomavirus negative high grade cervical lesions and cancers: Suggested guidance for HPV testing quality assuranceJournal of Clinical Virology, 2024
- First international proficiency study on human papillomavirus testing in cervical cancer screeningJournal of Clinical Virology, 2023
- HPV-Negative Adenocarcinomas of the Uterine Cervix: From Molecular Characterization to Clinical ImplicationsInternational Journal of Molecular Sciences, 2022
- Human Papillomavirus Infection Determines Prognosis in Cervical CancerJournal of Clinical Oncology, 2022
- Audit of laboratory sensitivity of human papillomavirus and cytology testing in a cervical screening programInternational Journal of Cancer, 2021
- High-risk human papillomavirus status and prognosis in invasive cervical cancer: A nationwide cohort studyPLOS Medicine, 2018
- Long term duration of protective effect for HPV negative women: follow-up of primary HPV screening randomised controlled trialBMJ, 2014